Wedbush raises TScan Therapeutics' PT to $5, maintains Outperform rating.

jueves, 5 de marzo de 2026, 9:04 am ET1 min de lectura
TCRX--

Wedbush raises TScan Therapeutics' PT to $5, maintains Outperform rating.

Wedbush raises TScan Therapeutics' PT to $5, maintains Outperform rating.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios